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OBJECTIVES This study was conducted to evaluate the effect of revascularization on survival in patients
with congestive heart failure (CHF) due to ischemic left ventricular (LV) systolic dysfunction
based on the presence of myocardial viability (MV).
BACKGROUND There are insufficient data regarding the survival benefit of revascularization in patients with
CHF due to ischemic LV systolic dysfunction.
METHODS Follow-up was obtained in 87 consecutive patients with CHF due to ischemic LV systolic
dysfunction (New York Heart Association [NYHA] class II-IV; LV ejection fraction ,0.35)
who underwent low-dose dobutamine echocardiography (DE). MV within each of 12
myocardial segments representing the LV was defined as having either: 1) normal function or
mild dyssynergy at rest; 2) severe resting dyssynergy that improved on DE, or 3) worsening
of function on DE except in the case of akinesia.
RESULTS At a mean follow-up of 40 6 17 months, 37 patients had received revascularization on the
basis of clinical grounds, and there were 22 (25%) cardiac-related deaths. Multivariate Cox
regression analysis revealed that when patients with at least five segments showing MV
underwent revascularization, mortality was reduced by an average of 93% (confidence interval
of 22% to 99%), which was associated with improvement in NYHA class as well as LV
ejection fraction. Patients with less than five segments showing MV who underwent
revascularization (and thus, showing mostly scar), and those with at least 5 segments
demonstrating MV who were treated medically, had a much higher mortality.
CONCLUSIONS Revascularization produces a clear survival benefit in patients with CHF due to ischemic LV
systolic dysfunction who have a significant region of the LV demonstrating MV. These data
may have wide-ranging implications in the management of patients with coronary artery
disease whose main clinical presentation is CHF. (J Am Coll Cardiol 1999;33:1848–54) ©
1999 by the American College of Cardiology
In some patients with coronary artery disease (CAD), the
main symptom may be dyspnea rather than angina. In many
instances, these patients may also manifest signs of conges-
tive heart failure (CHF). They are usually treated with
diuretics, digoxin and more recently, with ACE inhibitors.
Because they do not complain of angina, workup for
reversible ischemic left ventricular (LV) dysfunction is many
times not even instituted. With the aging population,
chronic ischemic LV dysfunction has reached epidemic
proportions, and is now the leading cause of CHF in the
western hemisphere (1,2).
It is now recognized that revascularization provides both
symptomatic relief and mortality benefit in patients with
angina and ischemic LV systolic dysfunction (3–7). Ischemia
in these patients can be documented on exercise electrocardio-
gram (ECG) (8,9). Most patients with CHF, however, are
unable to exercise to work loads that can manifest ischemia on
the ECG. Baseline abnormalities on the ECG also preclude
interpretation of minor exercise-induced changes in many
instances. Thus, recognition of viable but potentially ischemic
myocardium is problematic in this cohort of patients. Without
evidence for ischemia, physicians are reluctant to consider
revascularization as an option, because LV systolic dysfunction
in these patients is presumed to be due to multiple infarctions.
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Echocardiography is a reliable clinical means for assessing
regional LV function. If regional LV function is normal or
only mildly reduced, myocardial viability (MV) is known to
be present (10). When resting regional LV function is
severely reduced, however, it is not possible to differentiate
MV from scar. The response of severely dysfunctional
myocardium to dobutamine has been shown to predict MV
in patients post–myocardial infarction (10–13), and those
with chronic ischemic LV dysfunction (14–18). The pur-
pose of our study was to assess the interaction between the
amount of MV (defined by regional LV function at rest and
during dobutamine) and revascularization in terms of its
effect on long-term outcome in patients with chronic CAD
whose main clinical presentation is CHF. The hypothesis
tested was that revascularization would not only improve
symptoms and regional LV function, but would also provide
a survival benefit if sufficient MV was present. Conversely,
providing revascularization to a severely dysfunctional LV
that did not have enough MV would not be beneficial.
METHODS
Patient selection. Eighty-seven consecutive outpatients at
Northwick Park Hospital were included in this study. All
patients gave written informed consent to participate in the
study. To be included in the study, three inclusion criteria
needed to be met: 1) CHF (NYHA class II-IV) for at least
three months that was treated medically; 2) LV ejection
fraction #0.35, and 3) clinical evidence of CAD (usually
prior infarction, and in some cases documented ischemia on
exercise testing). Patients with significant valvular disease,
unstable angina, myocardial infarction within three months,
sustained ventricular tachycardia or atrial fibrillation were
excluded from the study. All patients underwent clinical
assessment, rest echocardiography, low-dose dobutamine
echocardiography (DE), coronary angiography and prospec-
tive follow-up.
Echocardiography. Echocardiographic images were ac-
quired in the standard parasternal long and short axis as well
as apical four- and two-chamber views. LV ejection fraction
at rest was estimated from the apical views using the
modified Simpson’s method previously validated in our
laboratory (19). Dobutamine was infused intravenously
starting at 5 mg/kg/min, and increased to 10 and then 15
mg/kg/min, with each dose maintained for 5 min (13).
Although imaging was performed continuously, data were
acquired only at baseline and during the last minute of each
dobutamine dose.
Images were analyzed in a quad-screen cine-loop format
(14) by two experienced observers blinded to all other
clinical information. Systolic wall thickening (SWT) was
graded in each of 12 myocardial segments (Fig. 1) as: 1 5
normal; 2 5 mild hypokinesia; 3 5 severe hypokinesia; and
4 5 akinesia (20) using a consensus opinion. SWT index
was calculated by summing the grades of all segments that
were visualized and dividing this sum by the number of
segments visualized. The segments ascribed to each of the
three vascular vascular territories are mentioned in the
legend to Figure 1.
For MV to be considered present within a myocardial
segment, one or more of the following criteria had to be
met: 1) normal (grade 1) or mildly reduced (grade 2) systolic
function at rest (10,18); 2) improvement in systolic function
during DE by $1 grade when systolic function was severely
reduced (grade #3 [14]); or, 3) worsening of systolic
function on DE (indicating inducible ischemia, and thus
also MV [18]), except when akinesia (grade 5 4) was
present at rest (10).
Coronary angiography. CAD was defined as $50% lumi-
nal diameter narrowing of a major epicardial coronary artery
or its major branch. Each patient was classified as having
one-, two- or three-vessel disease. In addition, a coronary
jeopardy score was calculated based on dividing the coronary
tree into six segments and giving each segment with a
$75% stenosis, or any segment distal to such a stenosis, a
score of 2. In patients with a left dominant system, the right
coronary artery was assigned no score. The maximal possible
score in any patient was 12 (21).
Follow-up. All patients underwent clinical assessment at a
mean of 21 months after entering the study. Survival status
Abbreviations and Acronyms
ACE 5 angiotensin converting enzyme
CAD 5 coronary artery disease
CHF 5 congestive heart failure
DE 5 dobutamine echocardiography
ECG 5 electrocardiography
LV 5 left ventricle; left ventricular
NYHA 5 New York Heart Association
MV 5 myocardial viability
SWT 5 systolic wall thickening
Figure 1. The 12-segment model used for echocardiographic
assessment of resting function and function during DE. Segments
1, 2, 6, 7 and 11 belong to the left anterior descending artery
vascular territory. Segments 3 and 8 belong to the left circumflex
artery territory. Segments 4, 5, 9 and 10 belong to the right
coronary artery territory. Segment 12 belongs to the left anterior
descending artery territory, unless it is abnormal in conjunction
with other segments of the right coronary artery and not the left
anterior descending artery territory, in which case it belongs to the
right coronary artery territory.
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was determined at a mean of 40 months by contacting the
patient or next of kin. The cause of death was established by
review of hospital records or from the patient’s physician.
Cardiac deaths were defined as those resulting from acute
myocardial infarction, refractory CHF or occurring sud-
denly and not being attributed to other known causes.
Statistical methods. Continuous variables are expressed as
mean 6 1 SD, and categorical variables are expressed as
proportions. Survival data were assessed by Cox propor-
tional hazard models (22) to estimate the interaction of
revascularization with the extent of MV as well as with
other potential prognostic factors, and to characterize the
effects of these interactions on mortality. Univariate Cox
regression analysis was initially performed using clinical,
echocardiographic and angiographic variables. Multivariate
Cox regression analysis was then performed by entering into
the model variables that had a p value of ,0.10 on
univariate analysis. All variables with a p value of ,0.05
were allowed to remain in the final model.
A receiver-operator characteristics curve was plotted to
define the sensitivity and specificity of different cutoff points
for the number of viable segments that needed to be
revascularized to show survival benefit (23). Patients were
then classified into groups based on the best cutoff point and
the type of treatment offered (revascularization vs. medical
management). Baseline clinical characteristics (including
medical therapy), and echocardiographic as well as angio-
graphic data, were compared between these groups using
analysis of variance or Fisher exact test. Kaplan-Meier life
table analysis was performed to assess event-free survival
(24), which was compared between the four groups using
the Mantel-Cox test. A p value of ,0.05 (two-sided) was
considered significant.
RESULTS
Patient characteristics are listed in Table 1. More than three
fourths of the patients were male and had a history of
myocardial infarction. Only one fourth had chest pain,
despite the majority (81%) having multi-vessel CAD. Al-
most 90% were taking diuretics and ACE inhibitors. On
average, only one fourth of the 12 myocardial segments in
any patient demonstrated normal (grade 1) or mildly re-
duced (grade 2) systolic function; three fourths demon-
strated severe resting dysfunction (grade $3), which was
consistent with the low resting LV ejection fraction in these
patients. Less than half of the dysfunctional segments in
these patients showed improvement on DE. Most segments
showed no response (improvement or worsening) to DE.
Despite severe LV dysfunction, however, on an average
more than half of the segments showed MV based on the
combined assessment of resting and dobutamine-induced
wall thickening.
Of the 87 patients, 37 (43%) underwent revascularization,
of whom most (89%) underwent multiple coronary artery
bypass grafting. Percutaneous coronary angioplasty of the
left anterior descending coronary artery was performed in
four patients (11%), one of whom also had the procedure
performed on the left circumflex coronary artery. The mean
interval between DE and revascularization was 11 6 4
weeks. The DE results were not known to the clinicians
who determined the treatment option. One half of the 50
patients who did not receive revascularization had a plausi-
ble reason for not undergoing surgery: 13 were considered to
have poor distal vessels on angiography, 6 had severe
pulmonary disease and 6 refused surgery. Of the other half,
surgeons were reluctant to operate on 10 because of poor LV
ejection fraction and a high LV end-diastolic pressure, and
15 did not receive surgery because of lack of funds.
At a mean follow-up of 40 6 17 months, there were 22
(25%) cardiac-related deaths: 5 from acute myocardial
infarction, 14 from progressive CHF and 3 occurred sud-
denly. On Cox regression, the univariate predictors of
survival were the number of segments demonstrating MV,
number of viable segments in the right and left circumflex
coronary territories, occurrence of revascularization and the
interaction between MV and the occurrence of revascular-
Table 1. Patient Characteristics
Age, years (median, range) 62 (43–82)
Male (%) 79 (91%)
History of (%):
Essential hypertension 37 (43%)
Diabetes mellitus 25 (29%)
Hyperlipidemia 25 (29%)
Previous myocardial infarction 79 (91%)
Chest pain 22 (25%)
Medication (%):
Diuretics 76 (87%)
ACE inhibitors 75 (86%)




SWT index at rest 3.1 6 0.6
LV ejection fraction at rest 0.25 6 0.09
No. segments with grade 1 or 2 3.0 6 2.5
No. segments with grade 3 or 4 9.0 6 2.4
No. segments with improvement 4.0 6 3.6
No. segments with worsening 0.6 6 1.3
No. segments with no change 6.8 6 3.9
SWT index 5 mg/kg/min 2.9 6 0.6
SWT index at 10 mg/kg/min 2.7 6 0.6
SWT index at 15 mg/kg/min 2.5 6 0.7
No. viable segments in LAD territory 3.1 6 2.2
No. viable segments in RCA territory 2.4 6 1.7
No. viable segments in LCx territory 1.8 6 0.5
Total # viable segments 7.0 6 3.4
Angiographic Variables:
No. diseased arteries 2.3 6 0.8
Jeopardy score 7.9 6 2.7
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex artery; LV 5
left ventricular; RCA 5 right coronary artery; SWT 5 systolic wall thickening.
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ization when the number of segments showing MV was at
least five (Table 2). The last variable was the most important
independent predictor of survival on multivariate Cox re-
gression analysis. The only additional variable that was
predictive of survival on multivariate analysis was the base-
line NYHA class (Table 2).
The receiver-operator characteristic curve showing the
sensitivity and specificity of different cutoff points for the
number of segments with MV that needed to be revascu-
larized to note a survival benefit is depicted in Figure 2. In
keeping with the results of Cox regression analysis, a cutoff
point at at least four versus at least five segments with MV
showed the best sensitivity and specificity (75% and 91%,
respectively) for survival after revascularization.
According to these results, we divided our patients into
four groups based on MV (present in $5 of the 12
myocardial segments) and type of treatment offered (revas-
cularization vs. medical management): Group 1 (n 5 31)
had MV and underwent revascularization; Group 2 (n 5
32) had MV but were managed medically; Group 3 (n 5 6)
had no MV but underwent revascularization; and Group 4
Figure 2. The receiver-operator characteristic curve showing the
sensitivity (x-axis) and 1-specificity (y-axis) of the different cutoff
points for the number of segments with MV that needed to be
revascularized in order to demonstrate a survival benefit. a 5 0
segments, b 5 #2 versus $3 segments; c 5 #4 versus $5
segments; d 5 #5 versus $6 segments; e 5 #6 versus $7
segments; f 5 #7 versus $8 segments; g 5 #8 versus $9
segments; h 5 #9 versus $10 segments; i 5 #10 versus $11
segments; j 5 #11 versus $ segments; and k 5 12 segments.
Table 2. Cox Regression Analysis for Predicting Cardiac-related Mortality
Variable









Age (increase by 10 years) 1.0 (0.6–1.7) 1.0
Male 0.6 (0.2–1.9) 0.4
NYHA class 1.6 (0.9–2.9) 0.08 3.1 (1.2–7.8) 0.02
History of:
Hypertension 1.4 (0.6–3.3) 0.4
Diabetes mellitus 1.4 (0.6–3.4) 0.4
Prior infarction 1.4 (0.5–3.4) 0.5
Chest pain 0.6 (0.3–1.4) 0.3
Echocardiographic variables:
SWT index at rest 1.5 (0.6–3.3) 0.4
LV ejection fraction at rest 0.8 (0.4–2.1) 0.5
No. segments with grade 1 or 2 0.9 (0.7–1.1) 0.3
No. segments with grade 3 or 4 1.1 (0.9–1.3) 0.3
No. segments improving 0.4 (0.2–0.9) 0.03
No. segments worsening 0.7 (0.2–2.5) 0.6
No. segments with no change 1.1 (1.0–1.3) 0.04
SWT index at 5 mg/kg/min 1.7 (0.8–3.8) 0.2
SWT index at 10 mg/kg/min 1.8 (0.8–3.7) 0.1
SWT index at 15 mg/kg/min 1.6 (0.8–3.2) 0.2
No. viable segments in LAD territory 0.9 (0.7–1.1) 0.1
No. viable segments in RCA territory 0.7 (0.6–0.9) 0.02
No. viable segments in LCx territory 0.6 (0.3–1.0) 0.05
Total # viable segments 0.3 (0.14–0.73) 0.009
Angiographic variables:
No. diseased vessels 1.7 (0.7–3.7) 0.2
Jeopardy score 1.2 (0.9–1.4) 0.2
$5 viable segments 1 Revascularization 0.07 (0.005–0.78) 0.0007 0.03 (0.002–0.4) 0.009
*Only variables with p , 0.10 on univariate analysis are included. Abbreviations are the same as in Table 1.
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(n 5 18) had no MV and were treated medically. There
were no differences in any of the variables between the four
groups at the time of entry into the study (Table 3).
By 21 6 8 months, 7 patients had died and 10 did not
return for follow-up. Significant improvement in NYHA
functional class (1.5 6 0.6 vs. 2.5 6 0.6 at baseline p ,
0.001) and LV systolic function (SWT index of 2.6 6 0.9
vs. 3.1 6 0.6 at baseline, p , 0.01) were noted in the Group
1 patients, while no changes were observed in the other
three groups. In the Group 1 patients, there was a reduction
in diuretic use from 87% to 30% (p , 0.001) and nitrate
intake from 48% to 9% (p , 0.001), while reduction in use
of these drugs was not seen in the other groups. The use
of ACE inhibitors remained unchanged in all groups. At
a mean follow-up of 40 6 17 months, of the 22 patients
who died, 1 (3%) belonged to Group 1, 10 (31%) to
Group 2, 3 (50%) to Group 3 and 8 (44%) to Group 4
(Table 3). Group 1 mortality was significantly (p ,
0.001) less compared with the other three groups. Figure
3 illustrates the Kaplan-Meier survival curves of the four
groups of patients.
DISCUSSION
The new finding of our study is that patients with CAD and
chronic LV systolic dysfunction whose main clinical presen-
tation is CHF show improvement in NYHA class, LV
systolic function and long-term outcome after revascular-
ization if they have sufficient MV on echocardiography. If
such patients are treated by conventional medical therapy,
their mortality is high, presumably from progressive isch-
emic LV dysfunction or an acute ischemic event. Con-
versely, if sufficient MV is lacking in the presence of severe
LV systolic dysfunction, revascularization provides no ben-
efit. Thus, echocardiography may have an important role in
patients with CHF for selecting those who may benefit
from revascularization.











Age, median (range) 63 (43–82) 60 (46–77) 64 (57–67) 62 (48–76)
Male (%) 29 (94%) 29 (91%) 6 (100%) 15 (83%)
History of (%):
Essential hypertension 13 (42%) 14 (44%) 5 (83%) 6 (33%)
Diabetes mellitus 12 (38%) 8 (26%) 3 (50%) 2 (11%)
Hyperlipidemia 5 (19%) 2 (7%) 1 (14%) 3 (15%)
Previous infarction 26 (84%) 30 (94%) 6 (100%) 17 (94%)
Chest pain 10 (32%) 7 (22%) 3 (50%) 2 (11%)
NYHA Class 2.5 6 0.6 2.2 6 0.9 2.5 6 0.5 2.4 6 0.9
Medications:
Diuretics 27 (87%) 28 (88%) 5 (83%) 16 (89%)
ACE inhibitors 25 (81%) 27 (84%) 6 (100%) 17 (94%)
Ca21 blockers 6 (19%) 7 (22%) 1 (17%) 1 (6%)
Nitrates 15 (48%) 12 (38%) 3 (50%) 5 (28%)
Digoxin 12 (39%) 10 (31%) 2 (33%) 9 (50%)
Resting LV function:
LV ejection fraction 0.25 6 0.08 0.26 6 0.09 0.24 6 0.09 0.24 6 0.09
SWT index 3.1 6 0.6 3.0 6 0.6 3.4 6 0.3 3.4 6 0.4
Jeopardy Score 8.2 6 2.9 7.6 6 2.5 8.1 6 2.8 7.7 6 2.6
No. diseased vessels 2.6 6 0.5 2.2 6 0.9 2.6 6 0.7 2.2 6 0.7
Cardiac-related death 1 (3%) 10 (31%) 3 (50%) 8 (44%)
No differences between groups except for cardiac death.
Figure 3. Event-free survival curves for the four patient groups.
See text for details. Solid diamond 5 revascularization with
myocardial viability; solid triangle 5 medical therapy with myo-
cardial viability; open triangle 5 medical therapy without
myocardial viability; open diamond 5 revascularization without
myocardial viability.
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The problem of CHF. There are ample data to support
the use of revascularization in patients with CAD and LV
systolic dysfunction who have angina. Such patients show
marked symptomatic relief as well as significant improve-
ment in long-term survival (3–6,25,26), and their regional
LV systolic function generally improves (4–6). The systolic
dysfunction can occur from either chronic reduction in
resting myocardial blood flow or repetitive ischemia, or both
(27). In either case, successful revascularization removes the
cause of dysfunction.
Many patients with CAD present with symptoms other
than angina. At times it is dyspnea on exertion from
transient LV systolic dysfunction caused by exercise-
induced ischemia. More often, the dyspnea is associated
with chronic LV systolic dysfunction and CHF, with angina
not being a major symptom. With people living longer lives,
and the prevalence of CAD being higher in them, the
incidence of chronic ischemic LV dysfunction is increasing
rapidly, so that the epidemiology of CHF has changed in
recent years from causes other than CAD to predominantly
CAD (1,2).
Admission (and readmission) for CHF is now the leading
cause of hospitalization in the western hemisphere (28).
Many of these patients have reversible ischemic LV dys-
function, and if revascularized, would show both symptom-
atic improvement and benefit from a longer life. The cost of
revascularization may offset the cost of repeated hospital-
izations and improve the quality of life. With modern
surgery and other forms of revascularization, elderly patients
are tolerating interventions much better (29). If surgery is
not an option, aggressive medical therapy to alleviate ischemia
and its sequelae, such as with carvedilol, may also provide
survival benefit (30). The challenge is to recognize the presence
of reversible LV systolic dysfunction in these patients.
Comparison with previous studies. There are remarkable
similarities between our results and those of Ragosta et al.
(6) and Pagley et al. (7) using 201thallium imaging. Similar
to us, they found only a minority of patients with chronic
ischemic LV dysfunction lacking evidence for MV. Using a
15-segment model of the LV, they found that if $7
dyssynergic segments exhibited MV, LV ejection fraction
was likely to improve after revascularization (6). Survival
benefit was seen only in patients undergoing revasculariza-
tion. Conversely, patients with sufficient MV who did not
undergo revascularization had a poor outcome (7).
Dobutamine echocardiography has also been used to
assess MV in chronic ischemic LV dysfunction. In all
studies, patients with MV had poor outcome on medical
therapy compared with revascularization (31–33). Williams
et al., however, reported less events in medically treated
patients with no MV compared with those with MV (31).
The difference between their study and ours could be
explained by the differences in the types of events. Whereas
we considered only cardiac-related death as events, they
included other soft points as well. Our results are very
similar to those of Afridi and colleagues, who demonstrated
improved survival in patients with CAD and severe LV
dysfunction who had both MV and revascularization (32).
Like us, they found lack of MV and revascularization to be
associated with poor outcome. Like Afridi et al. and us,
Meluzin et al. also showed that the beneficial effect of
revascularization was related to the amount of MV (33).
The major difference between our study and all previous
studies assessing the role of MV in LV dysfunction due to
CAD is that although these studies also included patients
with CHF, their major clinical presentation was angina. We
specifically studied patients whose main presentation was
CHF. Nonetheless, these studies combined with ours make
a strong argument for assessing MV in patients with
ischemic LV dysfunction irrespective of the presenting
symptom. Such an approach can guide management.
For scoring regional LV function, we selected a model in
which each myocardial segment is equivalent in weight (20).
Thus, when half the segments are involved, half the LV
myocardium is involved. The major difference between this
and some other models is the segmentation of the apex. In
our model, the apex is divided into two segments. Conse-
quently, some adjustments need to be made when interpret-
ing our results in the context of other segmentation
schemes.
Study limitations. Similar to previous studies (5–7,31,33),
this is a single-center study where selection bias is unavoid-
able. The patients were selected from an outpatient setting
and may not be as sick as those who seek repeated
hospitalizations for CHF. The number of patients in the
group who underwent revascularization in the absence of
MV is small. Also, the results may not be applicable to
populations where multi-vessel disease is less frequent. A
randomized design would undoubtedly be ideally suited for
a study such as this, but it is difficult, if not impossible, to
prospectively randomize patients with very poor LV systolic
function for surgery versus medical management.
In our study, the results of DE were not divulged to the
physician making the decision whether to revascularize or
not. Although no differences were noted between patients
undergoing revascularization and those receiving medical
management, selection bias may have favored taking one
group to surgery over another. Factors such as quality of
vessels on angiography, pulmonary status and the reluctance
to operate on patients with poor LV ejection fraction played
a role in our study. A significant number of patients also did
not receive surgery because of lack of funds.
We only used low-dose dobutamine in our study. We
were, therefore, unable to study the value of the “biphasic”
response on the prediction of survival. The “biphasic”
response indicates the presence of a physiologically signifi-
cant coronary stenosis proximal to viable myocardium (10),
and revascularization of myocardium showing this response
is highly predictive of functional recovery after revascular-
ization (16). However, a “biphasic” response can only be
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seen in segments that first demonstrate an improvement in
thickening, a criterion for MV in our study. Thus, segments
likely to ultimately show a “biphasic” response were consid-
ered viable in our study. Segments likely to demonstrate
ischemia on DE (worsening of function except in the
presence of akinesia) were also considered viable.
Conclusions. Patients with CHF due to LV systolic dys-
function from CAD who have sufficient MV on echocardi-
ography have a marked survival benefit from revasculariza-
tion compared with those with MV who do not undergo
revascularization or those without sufficient MV who un-
dergo revascularization. This survival benefit is also associ-
ated with improvement in NYHA class and global systolic
LV function. These data may have wide-ranging implications
in the management of patients with ischemic LV systolic
dysfunction whose main clinical presentation is CHF.
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